海爾生物(688139.SH):擬以5.472億元收購重慶三大偉業製藥90%股權
格隆匯 10 月 19日丨海爾生物(688139.SH)公佈,公司擬使用自有資金,通過擬新設立的全資子公司青島海爾血液技術有限公司(暫定名,最終以市場監督管理部門的工商登記信息為準,“新設子公司”),以人民幣5.472億元的對價收購自然人鍾世良先生持有的重慶三大偉業製藥有限公司(“重慶三大偉業”或“標的公司”)90%股權。
重慶三大偉業是國家定點生產藥品和醫療器械的專業企業,主要為血漿採集提供血漿分離機、一次性使用離心式血漿分離器及配套使用的輸血用枸櫞酸鈉注射液及氯化鈉注射液等,是國內少數具有采漿設備、耗材以及配套藥品等全系列採漿產品的企業之一。自成立以來,重慶三大偉業一直深耕血製品公司下屬的單採血漿站領域,在採漿行業擁有豐富的客户資源,建立了良好的用户口碑,是國內領先的採漿設備和採漿耗材供應商。
標的公司目前經營穩健,2019年營業收入為1.18億元,淨利潤為3318萬元,2020年1-7月營業收入為6262萬元,淨利潤為1718萬元。同時標的公司在單採漿行業處於國內領先水平,可以為客户提供包括設備、耗材和藥品全方位解決方案;且下游客户羣為大型生物製品公司,穩定性較好,因此標的公司能夠在原有的漿站細分領域持續保持穩定增長。
此次交易完成後,海爾生物在血液安全領域的用户場景不僅得以從醫院、血站向採漿站延伸,還能夠實現“設備+軟件+耗材+藥品”的綜合解決方案拓展,相關方案可應用於包括血站、醫院、採漿站等在內的血液安全全場景。通過與用户的高頻交互,公司能夠進一步增強用户粘性,提升服務廣度與深度,豐富延展血液安全生態佈局。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.